Active, not recruitingNot applicableNCT04192747

The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

Studying Cold agglutinin disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Elixir Medical Corporation
Principal Investigator
Shigeru Saito, MD
Chief Director, Shonan Kamakura General Hospital
Intervention
Percutaneous Coronary Intervention(device)
Enrollment
445 target
Eligibility
20 years · All sexes
Timeline
2020 – 2027

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04192747 on ClinicalTrials.gov

Other trials for Cold agglutinin disease

Additional recruiting or active studies for the same condition.

See all trials for Cold agglutinin disease →

← Back to all trials